References
Strader, D. B. et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39, 1147–1171 (2004).
Jensen, D. M. & Ascione, A. Future directions in therapy for chronic hepatitis C. Antivir. Ther. 13 (Suppl. 1), 31–36 (2008).
Vertex. Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment. Vertex web site [online], (2008).
HIV and Hepatitis.com. R7128 Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded. HIV and Hepatitis.com web site [online], (2008).
Modi, A. A. & Hoofnagle, J. H. New therapies for hepatitis C. Hepatology 46, 615–617 (2007).
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Melnikova, I. Hepatitis C therapies. Nat Rev Drug Discov 7, 799–800 (2008). https://doi.org/10.1038/nrd2661
Issue Date:
DOI: https://doi.org/10.1038/nrd2661
- Springer Nature Limited
This article is cited by
-
Reflections on a 40-year career in drug design and discovery
Medicinal Chemistry Research (2023)
-
Structure-based predictive model for some benzimidazole inhibitors of hepatitis C virus NS5B polymerase
Medicinal Chemistry Research (2013)
-
Emerging principles in protease-based drug discovery
Nature Reviews Drug Discovery (2010)